Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Bioventix reports 4% revenue decline after pressure from China

Bioventix reported a 4% revenue decline to £13.1m and a pre-tax profit of £10.1m for the year to 30 June 2025. The company attributes drops in biotin, progesterone and estradiol mainly to government procurement measures and price pressure in China, while its core vitamin D antibody business grew by 12%. Cash fell to £5.1m; the total dividend is 150 pence per share (prior year 155 pence). Bioventix expects slightly lower revenue for 2025/26 but sees growth potential in neurology and troponin tests. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, BIOVENTIX PLC LS -,05 has already paid €0.81 in dividends. The last payout was in April.

Financials

In the last quarter, BIOVENTIX PLC LS -,05 had revenue of €7.91m and net profit of €4.63m

(EUR)	June 2026	YoY
Revenue	7.91m	-
Gross profit	7.18m	-
Net profit	4.63m	-
EBITDA	6.04m	-

Fundamentals

Metric	Value
Market capitalization	€122.02m
Number of shares	5.22m
52-week high/low	€27.01 - €15.57
Dividend yield	7.34%
Dividends TTM	€1.72
Next dividend	€0.96
Beta	0.51
P/E ratio	13.45
PEG ratio	-1,211,313,003,223,788.80
P/B ratio	8.93
P/S ratio	7.85

Company profile

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.